ArticleRegenerative therapy2026
Hypoxia conditioned adipose-derived stem cell-derived extracellular vesicle therapy improves cardiac function in a rat model of ischemic cardiomyopathy.
Article in Regenerative therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Extracellular vesicles (EVs) are potential cell-free therapies for cardiac regeneration. Although adipose-derived stem cells (ADSCs) are easily obtained using minimally invasive procedures, therapeutic effects of hypoxically conditioned ADSC-derived EVs on the heart remain unknown. We aimed to verify whether hypoxic preconditioning enhances the therapeutic efficacy of ADSC-derived EVs. Methods: Lewis female rats were used to isolate ADSCs and establish an ICM rat model. ADSCs were cultured in a 48-h exosome-free medium under 5% or 20% O Results: Functional analysis of EV microRNAs suggested that hypoxia increased levels of miRNAs involved in suppressing fibrosis. Echocardiography at 2 and 4 weeks post-EV administration showed greater improvement in cardiac function (reduction in diastolic and systolic diameters, and improvement in left ventricular EF) in the hypoxic ADSC-derived EV group. Fibrosis reduced and vascularization increased in the hypoxic ADSC-derived EV group tissues. On day 2 after hypoxic ADSC-derived EV administration, RNA sequencing of myocardial infarction border zones showed increased expression of multiple genes associated with antifibrotic, anti-inflammatory, and angiogenic processes in the heart. GSEA identified increased expression of acute inflammatory responses. Conclusions: Hypoxic ADSC-derived EV administration induces acute inflammation and suppresses late-stage fibrosis by modulating immunity, thereby contributing to improved cardiac function. They may be an effective option for cardiac regenerative therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.